Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-03-21
2002-11-05
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S283000
Reexamination Certificate
active
06476043
ABSTRACT:
The present invention relates to the use of camptothecin derivatives, without entailing any gastrointestinal intolerance side effects, or with reduced gastrointestinal side effects. The present invention also relates to the use of sodium chloride solutions to reduce the gastrointestinal side effects entailed by the administration of camptothecin derivatives.
It is known that the administration of camptothecin derivatives causes many side effects. In particular in the gastrointestinal tract, they most commonly cause very serious vomiting and diarrhoea which can lead to interruption of the treatment.
European patent EP 137145 describes camptothecin derivatives of general formula:
in which, in particular, R
1
is hydrogen, halogen or alkyl, X is a chlorine atom or NR
2
R
3
in which R
2
and R
3
, which may be identical or different, can represent a hydrogen atom, an optionally substituted alkyl radical, a carbocycle or a heterocycle which are optionally substituted, or alkyl radicals (optionally substituted) forming, with the nitrogen atom to which they are attached, a heterocycle optionally containing another hetero atom chosen from O, S and/or NR
4
, R
4
being a hydrogen atom or an alkyl radical, and in which the X—CO—O— group is located in positions 9, 10 or 11 on ring A. These camptothecin derivatives are anticancer agents which inhibit topoisomerase I, among which irinotecan, for which X—CO—O— is [4-(1-piperidino)-1-piperidino]carbonyloxy, is an active principle which is particularly effective on solid tumours and especially colorectal cancer.
Patent application EP 74256 also describes other camptothecin derivatives which are also mentioned as anticancer agents, in particular derivatives which have a structure similar to the structure given above and in which X—CO—O— is replaced with a radical —X′R′ for which X′ is O or S, and R′ is a hydrogen atom or an alkyl or acyl radical. Other camptothecin derivatives have also been described, for example, in patents or patent applications P 56692, EP 88642, EP 296612, EP 321122, EP 325247, EP 540099, EP 737686, WO 9003169, WO 9637496, WO 9638146, WO 9638449, WO 9700876, U.S. Pat. No. 7104894, JP 57 116015, JP 57 116074, JP 59 005188, JP 60 019790, JP 01 249777, JP 01246287, JP 91/12070, or in Canc. Res., 38 (1997) Abst. 1526 or 95 (San Diego—12-16 April), Canc. Res., 55(3), 603-609 (1995) or AFMC Int. Med. Chem. Symp. (1997) Abst. PE-55 (Seoul—27 July-1 August).
Camptothecin derivatives are conventionally administered by injection, more particularly intravenously in the form of a sterile solution or of an emulsion. Camptothecin derivatives can also be administered orally, in the form of solid or liquid compositions.
Camptothecin derivatives can also be administered in combination with other anticancer agents, such as for example cisplatin, oxaliplatin, Tomudexo® (N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-theonyl-L-glutamic acid)), Taxotere® (docetaxel), 5-fluorouracyl and thymidilate synthase inhibitors.
Unfortunately, among the clinical side effects linked to treatment with camptothecin derivatives, the onset of diarrhoea (of grade 3 or 4), of cholinergic syndrome, of nausea or vomiting is especially noted. In particular, in 38% of patients, severe diarrhoea is observed, which can endanger the life of the patients as a result of dehydration and/or associated infection.
Many strategies have been implemented in order to combat intestinal toxicity due to the administration of the active principle and to reduce it, but these have proved unsuccessful hitherto. The result of this is that camptothecin derivatives can only be used by very experienced oncologists and only for certain categories of patients who can tolerate them.
It has now been found, and it is this which forms the subject of the present invention, that protection against the gastrointestinal lesions induced by treatment with camptothecin derivatives can be obtained by the administration of a sodium chloride solution. The protection results in the reduction or even the specific elimination of the gastrointestinal side effects, without the systemic exposure to the active principle or the antitumour activity being reduced.
REFERENCES:
patent: 4284579 (1981-08-01), Meischen et al.
patent: 4898886 (1990-02-01), Larraz
patent: 5225404 (1993-07-01), Giovannella et al.
patent: 06087746 (1994-03-01), None
patent: 9220353 (1992-11-01), None
patent: WO 96/11005 (1996-04-01), None
Wagener et al, Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study, Annals of Oncology, vol. 6, No. 2, pp. 129-132, 1995.*
Wagener D.J.T., et al., Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study, Annals of Oncology, vol. 6, No. 2, pp. 129-132 (1995).
Guffroy Magali
Toutain Hervé
Aventis Pharma S.A.
Finnegan Henderson Farabow Garrett & Dunner LLP
Pryor Alton
LandOfFree
Use of camptothecin derivatives, with reduced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of camptothecin derivatives, with reduced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of camptothecin derivatives, with reduced... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2935787